劲方医药-B：2025年亏损收窄、现金充裕，差异化泛RAS管线即将发力，维持买入-20260326

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data readouts for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - The company is projected to generate revenue of RMB 1.30 billion in 2025, a 24% year-on-year increase, primarily from overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is forecasted to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is expected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - Revenue projections for 2026E are set at USD 85 million, with gross profit expected to be USD 33 million, maintaining a gross margin of 39.3% [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of registration studies for non-small cell lung cancer (NSCLC). Additionally, the confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are highlighted as key developments [6][12].